Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Neurological Events Reported after COVID-19 Vaccines: An Analysis of Vaccine Adverse Event Reporting System
Ann Neurol 91:756-771, Frontera, J.A.,et al, 2022
US Case Reports of Cerebral Venous Sinus Thrombosis with Thrombocytopenia after Ad26.COV2.S Vaccination, March 2 to April 21, 2021
JAMA 325:2448-2456,2445, See, I.,et al, 2021
Vaccine-Induced Thrombocytopenia with Severe Headache
NEJM 385:doi:10.1056/NEJMc2112974, Salih, F.,et al, 2021
Reversible Cerebral Vasoconstriciton Syndrome
www.UptoDate.com, June, Singhal, A., 2019
Hemi Orolingual Angioedema after tPA Administration for Acute Ischemic Stroke
West J Emerg Med 16:175-177, Madden, B. & Chebl, R.B., 2015
Remote or Extraischemic Intracerebral Hemorrhage - An Uncommon Complication of Stroke Thrombolysis
Stroke 45:1657-1663, Mazya, M.V.,et al, 2014
Disturbances of Cerebrospinal Fluid, Including Hydrocephalus, Pseudotumor Cerebri, and Low-Pressure Syndromes, Pseudotumor Cerebri
Adams & Victors Principles of Neurology, Chp 30, pg 628, Ropper, A.H.,et al, 2014
Thrombolysis Despite Recent Stroke
Stroke 44:1736-1738, Alhazzaa, M.,et al, 2013
Symptomatic Intracranial Hemorrhage after Stroke Thrombolysis: The SEDAN Score
Ann Neurol 71:634-641, Strbian,D.,et al, 2012
Multimodal Imaging of Reversible Cerebral Vasoconstriction Syndrome: A Series of 6 Cases
AJNR 33:1403-1410, Marder, C.P.,et al, 2012
Intravenous Thrombolytic Therapy for Acute Ischemic Stroke
NEJM 364:22, Wechsler, L.R., 2011
Cerebral Venous Sinus Thrombosis Associated with Cerebral Hemorrhage Is Anticoagulant Treatment Safe?
The Neurologist 17:208-210, Fuentes, B.,et al, 2011
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
Reversible Cerebral Vasoconstriction Syndrome
Pract Neurol 9:256-267, Ducros,A. &Bousser,M.-G., 2009
Thrombolysis with Alteplase 3 to 4.5 Hours After Acute Ischemic Stroke
NEJM 359:1317-1329,1393, Hacke,W.,et al, 2008
Risk Factors of Cerebral Vein and Sinus Thrombosis
Front Neurol Neurosci 23:23-54, de Freitas, G.R. & Bogousslavsky, J., 2008
The Safety of Hospital Stroke Care
Neurol 68:550-555,542, Holloway,R.G.,et al, 2007
Narrative Review: Reversible Cerebral Vasoconstriction Syndromes
Ann Intern Med 146:34-44, Calabrese,L.H.,et al, 2007
The Clinical and Radiological Spectrum of Reversible Cerebral Vasoconstriction Syndrome. A Prospective Series of 67 Patients
Brain 130:3091-3101, Ducros, A.,et al, 2007
Thromboembolic Adverse Events After Use of Recombinant Human Coagulation Factor VIIa
JAMA 295:293-298, OConnell,K.A.,et al, 2006
Tamoxifen:A New Risk Factor for Cerebral Sinus Thrombosis
Neurol 62:334-335, Masjuanh,J.,et al, 2004
Telemedicine for Acute Stroke
Stroke 34:725, LaMonte,M.P.,et al, 2003
Arterial Thrombosis Induced by IVIg and Its Treatment with tPA
Neurol 60:1825-1826,1736, Okuda,D.,et al, 2003
Tissue Plasminogen Activator for Acute Ischemic Stroke in Clinical Practice
Stroke 34:2847-2850, Graham,G.D., 2003
Cerebral Sinus Thrombosis with Tamoxifen
Neurol 56:1113-1114, Finelli,P.F. & Schauer,P.K., 2001
Safety of Intra-Arterial Thrombolysis in the Postoperative Period
Stroke 32:1365-1369, Chalela,J.A.,et al, 2001
Intravenous Tissue-Type Plasminogen Activator Therapy for Ischemic Stroke
Arch Neurol 58:2009-2013, Grotta,J.C.,et al, 2001
Superior Sagittal Sinus Thrombosis Due to Lithium:Local Urokinase Thrombolysis Treatment
Neurol 54:532-533, Wasay,M.,et al, 2000
Treating Acute Stroke Patients with Intravenous tPA, The OSF Stroke Network Experience
Stroke 31:77-81, Wang,D.Z.,et al, 2000
Cerebral Venous Thrombosis Associated with Epoetin Alfa Therapy
Arch Neurol 57:260-262, Finelli,P.F.&Carley,M.D., 2000
Intravenous Tissue-Type Plasminogen Activator for Treatment of Acute Stroke
JAMA 283:1145-1150,1189, Albers,G.W.,et al, 2000
Use of Tissue-Type Plasminogen Activator for Acute Ischemic Stroke
JAMA 283:1151-1158,1189, Katzan,I.L.,et al, 2000
Cerebral Venous Thrombosis,Combined Intrathrombus rtPA and Intravenous Heparin
Stroke 30:489-494,481, Frey,J.L.,et al, 1999
Initial Clinical Experience with IV Tissue Plasminogen Activator for Acute Ischemic Stroke:A Multicenter Survey
Neurol 53:424-427, Tanne,D.,et al, 1999
Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset, The ATLANTIS Study:A Randomized Controlled Trial
JAMA 282:2019-2026, Clark,W.M.,et al, 1999
Thrombolysis-Related Intracranial Hemorrhage, Analysis of 224 Cases from GUSTO-1 Trial with Clin Correl
Stroke 29:563-569, Gebel,J.M.,et al, 1998
PROACT:Recombinant Pro-Urokinase by Direct Arterial Delivery in Acute MCA Stroke
Stroke 29:4-11, delZoppo,G.J.,et al, 1998
I. V. t-PA for Acute Ischemic Stroke, Feasibility, Safety & Efficacy in the First Year of Clinical Practice
Stroke 29:18-22, Chiu,D.,et al, 1998
Brain SPECT with HMPAO & Safety of Thrombolytic Therapy in Acute Ischemic Stroke
Stroke 28:1830-1834, Alexandrov,A.V.,et al, 1997
Systematic Review of Evidence on Thrombolytic Therapy for Acute Ischaemic Stroke
Lancet 350:607-614, Wardlaw,J.M.,et al, 1997
Thrombolytic Therapy for Acute Ischemic Stroke-Summary Statement
Report of the Quality Standards Subcommittee of the AAN, Neurol 47:835-8391996., , 1996
Tissue-Type Plasminogen Activator Should Not be Used in Acute Ischemic Stroke
Arch Neurol 53:1306-1308, Riggs,J.E., 1996
Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Acute Hemispheric Stroke:The ECASS
JAMA 274:1017-1025, 10581995., Hacke,W.,et al, 1995
Randomised Contr Trial of Streptokinase
Aspirin & Comb in Trtm of Acute Ischaemic Stroke, Multictr Acute Stroke Trial-Italy, Lancet 346:1509, 15145,1504,1995., 1995
Venous Sinus Thrombosis Associated with Androgens in a Healthy Young Man
Stroke 25:212-213, Jaillard,A.S.,et al, 1994
Early Computed Tomographic Findings for Thrombolytic Therapy in Patients with Acute Brain Embolism
Stroke 23:20-23, Okada,Y.,et al, 1992
The Risk of Stroke in Patients with Acute Myocardial Infarction after Thrombolytic and Antithrombotic Treatment
NEJM 327:1-6, Maggioni,A.P.,et al, 1992
Urgent Therapy for Stroke Part II, Pilot Study of Tissue Plasminogen Activator Administered 91-180 Minutes from Onset
Stroke 23:641-645, Haley,E.C.,et al, 1992